EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio
February 06, 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio
January 09, 2024 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio
December 26, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue...
EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology
December 12, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...
EC-Logo-2018_TM_CMYK.jpg
Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
November 15, 2023 08:15 ET | electroCore, Inc.
ROCKAWAY, N.J., Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical...
EC-Logo-2018_TM_CMYK.jpg
electroCore Announces Third Quarter 2023 Financial Results
November 08, 2023 16:01 ET | electroCore, Inc.
Record third quarter 2023 net sales of $4.5 million, an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5...
EC-Logo-2018_TM_CMYK.jpg
electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
November 07, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger,...
FIGURE 1
Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting
October 24, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced top line data from an abstract...
EC-Logo-2018_TM_CMYK.jpg
electroCore Announces Two-Year Extension of gammaCore™ Device Listing in the NHS Supply Chain Catalogue
October 17, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial stage bioelectronic medicine and wellness company, announced today that gammaCore therapy will...
EC-Logo-2018_TM_CMYK.jpg
electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology
October 11, 2023 08:00 ET | electroCore, Inc.
ROCKAWAY, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and...